| Name | AC-262536 |
| Description | AC-262536 is a selective androgen receptor (SAR) modulator and exhibits potent agonist activity at the androgen receptor. It has partial agonist activity with respect to testosterone and suppresses luteinizing hormone. |
| In vitro | AC-262536 inhibits dihydroxytestosterone (DHT)-induced proliferation of LNCaP in a dose-dependent manner. The effects are significant with 100 nM, and reaches a plateau with 1 μM[2]. |
| In vivo | In male sprague-dawley rats, administration of AC-262536 (subcutaneous injection, once daily for 14 consecutive days) significantly decreased LH levels by about 40% at the 3 mg/kg dose. At the 10 and 30 mg/kg doses, the effects of AC-262536 were significantly stronger than Testosterone Propionate (TP) : 1.91±0.32 ng/mL and 1.53±0.34 ng/mL vs. 3.12±0.69 ng/mL, respectively[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 1 mg/mL (3.59 mM), Sonication is recommended.
DMSO : 50 mg/mL (179.63 mM), Sonication is recommended.
|
| Keywords | SARM | receptor | non-steroidal | modulator | Inhibitor | inhibit | AndrogenReceptor | Androgen Receptor | androgen | anabolic | AC-262536 | AC 262536 |
| Inhibitors Related | Dehydroisoandrosterone 3-acetate | Bicalutamide | 2-Ethylhexyl trans-4-methoxycinnamate | S-23 | Enzalutamide | Octinoxate | Testosterone propionate | Allura Red AC | Sunset Yellow FCF | Ostarine | 2-sec-Butylphenol | Flutamide |
| Related Compound Libraries | Nuclear Receptor Compound Library | Bioactive Compound Library | Endocrinology-Hormone Compound Library | Anti-Prostate Cancer Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Cancer Compound Library | Transcription Factor-Targeted Compound Library |
United States
